Support for Biomarkers in Guiding Checkpoint Inhibitor Rx in NSCLC

Chicago—In the first-line treatment of non-small cell lung cancer (NSCLC), new studies suggest that biomarkers for checkpoint ligand PD-L1 expression and tumor mutational burden (TMB) will guide how they are used. For patients with advanced lung cancer without epidermal growth factor receptor (EGFR) or ALK mutations, checkpoint inhibitor therapy is a standard of care, but the biomarkers appear useful for deciding whether to use checkpoint inhibitors alone or combined with another